ER、VEGF、MVD在肺癌组织中的表达及其临床意义

目的探讨雌激素受体(ER)与血管内皮生长因子(VEGF)在非小细胞肺癌(NSCLC)中的表达及其与生物学行为的关系。方法76例临床资料完整的肺癌手术切除标本,采用免疫组化方法检测其中ER、VEGF及微血管密度(MVD)的表达情况。结果76例NSCLC的ER的阳性表达率为69.7%(53/76),VEGF的阳性表达率为48.7%(37/76)。临床分期低、无淋巴结转移和中高分化的ER表达要高于临床分期高、有淋巴结转移和低未分化的的肺癌组织,临床分期低、有淋巴结转移和低未分化的VEGF和MVD的表达要高于临床分期低、无淋巴结转移和中高分化的的肺癌组织,差异均具有统计学意义(P<0.05),并且ER的表达与VEGF和FⅧ的表达呈负相关。结论肺癌组织中ER、VEGF和MVD可能在非小细胞肺癌的发生、发展中共同起作用。联合检测可作为评价非小细胞肺癌恶性程度和预后的共同指标。

The expression of ER, VEGF and MVD in non - small cell lung cancer and their clinical signifcance

Objective To evaluate the expression of ER, VEGF and MVD in human non - small cell lung cancer （NSCLC） and investigate its correlation with histopathological features. Methods The expression ER,VEGF and MVD in cancer tissues in 76 NSCLC patients with complete clinical data was evaluated by immunohistoehemitry methods. Results The positive rates of ER and VEGF in NSCLC were 69.7% and 48.7%. The expression of ER, VEGF, FⅧhave significant correlation with some pathological characteristics such as TNM classification, lymph nodes metastasis and the degree of differentiation. ER expession are negative correlated with VEGF and FⅧ expression. Conclusion ER, VEGF and MVD may play certain roles in the oneogenesis and progression of NSCLC. They may be used as a hopeful marker for predicting the metastasis potential of NSCLC.